BlackBarn Capital Partners LP 13F: Quarter-over-Quarter Portfolio Changes
BlackBarn Capital Partners LP reported a disclosed portfolio value of approximately $332.4 million in its latest SEC Form 13F-HR filing for Q1 2026, up 19.2% quarter on quarter. Over the quarter, the fund initiated 4 new positions, bought more shares in 6 holdings, trimmed 3 holdings, and exited 1 position.
BlackBarn Capital Partners LP's top buy was a new stake in Veeco Instrs INC Del (VECO) , equal to 10.2% of the disclosed portfolio. Its top sell was Axcelis Technologies INC (ACLS) . The fund exited the position completely after it had accounted for 2.8% of the previous portfolio.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| VEECO INSTRS INC DEL | VECO | 10.2% | History → |
| NXP SEMICONDUCTORS N V | NXPI | 3.6% | History → |
| GLOBAL BUSINESS TRAVEL GROUP | GBTG | 3.4% | Holders → |
| VIVID SEATS INC | SEAT | 0.9% | Holders → |
Top BuysQ1 2026
The fund's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| MCGRAW HILL INC | MH | +0.3% | +49.2% | History → |
| ARBUTUS BIOPHARMA CORP | ABUS | +0.2% | +35.1% | Holders → |
| PRIVIA HEALTH GROUP INC | PRVA | +-1.2% | +21.9% | History → |
| NIQ GLOBAL INTELLIGENCE PLC | NIQ | +-3.5% | +15.3% | History → |
| VIKING THERAPEUTICS INC | VKTX | +-0.9% | +13.0% | History → |
| AMNEAL PHARMACEUTICALS INC | AMRX | +-0.9% | +5.1% | History → |
Top SellsQ1 2026
The fund's top sells among positions it retained in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| DIVERSIFIED HEALTHCARE TR | DHC | -1.7% | 26.3% | History → |
| ROIVANT SCIENCES LTD | ROIV | -5.0% | 25.9% | History → |
| COGENT COMM HOLDINGS INC | CCOI | -2.2% | 23.1% | Holders → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| AXCELIS TECHNOLOGIES INC | ACLS | 2.8% |
Net Portfolio Value ChangeQ1 2026
- $0.3BPrior quarter
- $0.3BCurrent quarter
- +$0.1BNet delta
- +19.2%% change
Methodology & FAQ
How BlackBarn Capital Partners LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for BlackBarn Capital Partners LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did BlackBarn Capital Partners LP buy in Q1 2026?
In Q1 2026, BlackBarn Capital Partners LP initiated 4 new positions (VEECO INSTRS INC DEL (VECO), NXP SEMICONDUCTORS N V (NXPI), GLOBAL BUSINESS TRAVEL GROUP (GBTG), VIVID SEATS INC (SEAT)); bought more shares of MCGRAW HILL INC (MH), ARBUTUS BIOPHARMA CORP (ABUS), PRIVIA HEALTH GROUP INC (PRVA), NIQ GLOBAL INTELLIGENCE PLC (NIQ), VIKING THERAPEUTICS INC (VKTX) — the largest 5 of 6 adds.
What stocks did BlackBarn Capital Partners LP sell in Q1 2026?
In Q1 2026, BlackBarn Capital Partners LP fully sold 1 position (AXCELIS TECHNOLOGIES INC (ACLS)); reduced holdings in DIVERSIFIED HEALTHCARE TR (DHC), ROIVANT SCIENCES LTD (ROIV), COGENT COMM HOLDINGS INC (CCOI).
Which positions did BlackBarn Capital Partners LP initiate in Q1 2026?
BlackBarn Capital Partners LP established 4 new positions in Q1 2026: VEECO INSTRS INC DEL (VECO, 10.2%), NXP SEMICONDUCTORS N V (NXPI, 3.6%), GLOBAL BUSINESS TRAVEL GROUP (GBTG, 3.4%), VIVID SEATS INC (SEAT, 0.9%).
Which existing positions saw the largest allocation increases for BlackBarn Capital Partners LP in Q1 2026?
Of 6 existing positions with share-count increases in Q1 2026, the largest were: MCGRAW HILL INC (MH, +0.3% weight, +49.2% shares), ARBUTUS BIOPHARMA CORP (ABUS, +0.2% weight, +35.1% shares), PRIVIA HEALTH GROUP INC (PRVA, +-1.2% weight, +21.9% shares), NIQ GLOBAL INTELLIGENCE PLC (NIQ, +-3.5% weight, +15.3% shares), VIKING THERAPEUTICS INC (VKTX, +-0.9% weight, +13.0% shares), AMNEAL PHARMACEUTICALS INC (AMRX, +-0.9% weight, +5.1% shares).
Which positions did BlackBarn Capital Partners LP fully exit in Q1 2026?
BlackBarn Capital Partners LP fully exited 1 position in Q1 2026: AXCELIS TECHNOLOGIES INC (ACLS, last-reported weight 2.8%).
Which existing positions saw the largest allocation reductions for BlackBarn Capital Partners LP in Q1 2026?
Of 3 existing positions with share-count reductions in Q1 2026, the largest were: DIVERSIFIED HEALTHCARE TR (DHC, -1.7% weight, -26.3% shares), ROIVANT SCIENCES LTD (ROIV, -5.0% weight, -25.9% shares), COGENT COMM HOLDINGS INC (CCOI, -2.2% weight, -23.1% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.